+17% growth in sales in 2017 up to €21.6 million

+17% growth in sales in 2017 up to €21.6 million

+17% growth in sales in 2017 up to €21.6 million

+17% growth in sales in 2017 up to €21.6 million

12 January 2018 / 18 h 00

-- Strong International growth: +42% up to €2.4 million
-- Continued growth in Europe: +14% up to €19.2 million
-- More than 60,500 SpineJack® implants sold since 2011

Toulouse, January 12th, 2018 (6:00 PM CEST) – VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated sales results for the full year 2017, as of December 31st, 2017.

 

 

Sales Numbers 2017

2017 sales results, increasing by +17% to €21.6 million, performs below the expectations of the management which anticipated an annual growth of +30%. The difference is primarily due to difficulties in penetrating the German market because of very low prices. Therefore, the profitability target for 2017 will not be achieved. The financial result will also be adversely affected in the amount of €5 million of exceptional expenses as part of the operation with Stryker (advisory fees).


Financial reporting schedule
2017 Financial results: April 30th, 2018²

  1. Cf. segment reporting applied since VEXIM switched to IFRS consolidated financial statements.
  2. Indicative date, subject to changes.